May 15th 2024
Rohan Garje, MD, discusses emerging biomarkers in metastatic castration-resistant prostate cancer and where the treatment field is headed.
May 14th 2024
Rohan Garje, MD, discusses the utility of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.
May 4th 2024
Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.
April 23rd 2024
Rohan Garje, MD, discusses the evolving use of genomic testing and targeted treatment approaches in prostate cancer.